1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
    Neuronal Signaling
  3. TRP Channel
  4. TRPV Isoform
  5. TRPV Antagonist

TRPV Antagonist

TRPV Antagonists (18):

Cat. No. Product Name Effect Purity
  • HY-12245
    SB-366791
    Antagonist 98.72%
    SB-366791 is a potent and selective vanilloid receptor (VR1/TRPV1) antagonist (IC50=5.7 nM). SB-366791 can be used for the research of inflammation.
  • HY-18662
    RQ-00203078
    Antagonist 99.84%
    RQ-00203078 is a highly selective, potent and orally active TRPM8 antagonist with IC50s of 5.3 nM and 8.3 nM for rat and human TRPM8 channels, respectively. RQ-00203078 shows little inhibitory action against TRPV1, TRPA1, TRPV4, or TRPM2 channels.
  • HY-P1651A
    SOR-C13 TFA
    Antagonist 99.18%
    SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.
  • HY-108453
    5-Iodoresiniferatoxin
    Antagonist
    5-Iodoresiniferatoxin (I-RTX) is a selective TRPV1 antagonist, with an IC50s of 0.7 and 5.4 nM for rat and human receptors, respectively. 5-Iodoresiniferatoxin induces TRPV1-dependent hypothermia in vivo.
  • HY-10635
    ABT-102
    Antagonist
    ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain.
  • HY-132222
    SET2
    Antagonist 99.72%
    SET2 is a selective TRPV2 antagonist (IC50=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases.
  • HY-100129
    JNJ-17203212
    Antagonist 99.94%
    JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine.
  • HY-144372
    TRPV1 antagonist 3
    Antagonist 99.30%
    TRPV1 antagonist 3 (Compound 7q) is a potent TRPV1 antagonist with an IC50 of 2.66 nM against capsaicin. TRPV1 antagonist 3 is mode-selective, oral bioavailable (F = 60%) and CNS-penetrant.
  • HY-114017
    Vanilloid receptor antagonist 1
    Antagonist 98.07%
    Vanilloid receptor antagonist 1 is a potent vanilloid receptor TRPV1 antagonist extracted from patent US8349852B2, compound B8.
  • HY-131868
    TRPV3 antagonist 74a
    Antagonist ≥98.0%
    TRPV3 antagonist 74a is a potent and selective TRPV3 antagonist. TRPV3 antagonist 74a displays no significant activity against a panel of other ion channels. TRPV3 antagonist 74a can be used for the research of neuropathic pain.
  • HY-P1651
    SOR-C13
    Antagonist
    SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity.
  • HY-149823
    TRPV4 antagonist 4
    Antagonist
    TRPV4 antagonist 4 is a potent TRPV4 antagonist with an IC50 value of 22.65 nM. TRPV4 antagonist 4 inhibits TRPV4 current. TRPV4 antagonist 4 shows protective effects on acute lung injury.
  • HY-19589
    JTS-653
    Antagonist
    JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents.
  • HY-P1175A
    L-R4W2 TFA
    Antagonist
    L-R4W2 TFA is a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), with an IC50 of 0.1 μM. L-R4W2 TFA may act as a potent analgesic.
  • HY-P1175
    L-R4W2
    Antagonist
    L-R4W2 is a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), with an IC50 of 0.1 μM. L-R4W2 may act as a potent analgesic.
  • HY-W517163
    MK-2295
    Antagonist
    MK-2295 (NGD-8243) is a TRPV1 antagonist. MK-2295 is an analgesic agent, and can be used for research of pain.
  • HY-111218
    TRPV1 antagonist 5
    Antagonist
    TRPV1 antagonist 5 (compound 1) is a potent TRPV1 antagonist.
  • HY-12914
    V116517
    Antagonist
    V116517 is a potent, orally active transient receptor potential vanilloid (TRPV1) antagonist. V116517 shows potent activity in inhibiting both capsaicin (CAP)- and acid (pH 5)-induced currents in rat DRG neurons expressing native TRPV (IC50=423.2 nM for CAP; IC50=180.3 nM for acid). V116517 can be used for the research of pain.